CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Acute myeloid leukemia (AML) is a serious hematological malignancy requiring novel therapeutic strategies.
• Cyclin-dependent kinase 6 (CDK6), a cell cycle regulator, is implicated in leukemogenesis and maintaining leukemia stem cells (LSC).
• The prognostic value of CDK6 in AML, particularly non-acute promyelocytic leukemia (non-APL) subtypes, requires further elucidation.

Purpose of the Study:

• To investigate the role of CDK6 messenger RNA (mRNA) expression in AML.
• To evaluate CDK6 as a potential diagnostic and prognostic biomarker in non-APL AML patients.

Main Methods:

• Analysis of public databases and a validated cohort of AML patients.
• Correlation analysis of CDK6 expression with clinical parameters (blasts, FAB subtypes, CEBPA mutation, chromosomal abnormalities).
• Kaplan-Meier survival analysis to assess the impact of CDK6 on overall survival (OS).

Main Results:

• CDK6 mRNA levels were significantly overexpressed in AML cell lines and non-APL AML patients compared to healthy donors.
• CDK6 expression decreased in AML patients achieving complete remission (CR).
• CDK6 expression was inversely correlated with OS in non-APL AML patients and associated with specific genetic alterations and oncogenic genes, while negatively correlating with tumor-suppressive microRNAs.

Conclusions:

• CDK6 is upregulated in AML and associated with adverse prognostic factors.
• CDK6 expression levels correlate with treatment response and patient survival.
• CDK6 represents a promising diagnostic and prognostic biomarker for non-APL AML.